Otsuka Pharmaceutical Development & Commercialization, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$271.0M
Doctors Paid
9,266
Transactions
27,284
2024 Total
$12.3M
Payment Breakdown by Category
Research$247.2M (91.2%)
Consulting$20.0M (7.4%)
Food & Beverage$694,916 (0.3%)
Travel$485,993 (0.2%)
Royalty/License$198,678 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $247.2M | 7,528 | 91.2% |
| Consulting Fee | $20.0M | 3,269 | 7.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.6M | 592 | 0.6% |
| Grant | $705,020 | 22 | 0.3% |
| Food and Beverage | $694,916 | 13,763 | 0.3% |
| Travel and Lodging | $485,993 | 1,268 | 0.2% |
| Royalty or License | $198,678 | 8 | 0.1% |
| Charitable Contribution | $50,000 | 1 | 0.0% |
| Space rental or facility fees (teaching hospital only) | $28,190 | 13 | 0.0% |
| Education | $19,331 | 820 | 0.0% |
Payments by Type
Research
$247.2M
7,528 transactions
General
$23.8M
19,756 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF BREXPIPRAZOLE AS ADJUNCTIVE THERAPY IN THE MAINTENANCE TREATMENT OF ADULTS WITH MAJOR DEPRESSIVE DISORDER. | $22.7M | 22 | 364 |
| A TRIAL OF MULTIPLE-DOSES OF ARIPIPRAZOLE IN ADULTS WITH SCHIZOPHRENIA OR BIPOLAR 1 DISORDER | $17.0M | 0 | 19 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND TRIAL OF FIXED-DOSE BREXPIPRAZOLE AS COMBINATION THERAPY WITH SERTRALINE IN THE TREATMENT OF ADULTS WITH POST-TRAUMATIC STRESS DISORDER | $15.5M | 6 | 400 |
| PROTOCOL 331-201-00081 A MULTICENTER, RANDOMIZED, DOUBLE-BLIND TRIAL OF BREXPIPRAZOLE VERSUS PLACEBO FOR THE ACUTE TREATMENT OF MANIC EPISODES, WITH OR WITHOUT MIXED FEATURES, ASSOCIATED WITH BIPOLAR I DISORDER | $14.6M | 1 | 55 |
| PROTOCOL 331-201-00080 A MULTICENTER, RANDOMIZED, DOUBLE-BLIND TRIAL OF BREXPIPRAZOLE VERSUS PLACEBO FOR THE ACUTE TREATMENT OF MANIC EPISODES, WITH OR WITHOUT MIXED FEATURES, ASSOCIATED WITH BIPOLAR I DISORDER | $13.3M | 1 | 55 |
| A MULTICENTER, RANDOMIZED, FLEXIBLE-DOSE, DOUBLE BLIND TRIAL OF BREXPIPRAZOLE VERSUS PLACEBO FOR THE TREATMENT OF ADULTS WITH BORDERLINE PERSONALITY DISORDER | $8.3M | 24 | 310 |
| PHASE 3B, RANDOMIZED, OPEN-LABEL, SPONSOR-BLIND, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT, ONCE DAILY (QD) AND THREE TIMES WEEKLY (TIW) FOR THE MAINTENANCE TREATMENT OF ANEMIA IN HEMODIALYSIS SUBJECTS CONVERTING FROM ERYTHROPOIESIS-STIMULATING AGENTS (ESAS) | $7.4M | 5 | 200 |
| OPEN-LABEL TRIAL TO EVALUATE THE LONG TERM SAFETY OF TITRATED IMMEDIATE-RELEASE TOLVAPTAN IN SUBJECTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE | $7.0M | 1 | 107 |
| A MULTI-CENTER, RANDOMIZED, CONTROLLED TRIAL TO EVALUATE THE EFFECTIVENESS OF A DIGITAL THERAPEUTIC (CT-152) AS ADJUNCTIVE THERAPY IN ADULT SUBJECTS DIAGNOSED WITH MAJOR DEPRESSIVE DISORDER | $6.9M | 10 | 181 |
| AN OPEN-LABEL, 52-WEEK, MULTICENTER TRIAL EVALUATING THE LONG-TERM SAFETY AND TOLERABILITY OF CENTANAFADINE SUSTAINED-RELEASE TABLETS IN ADULTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER | $6.6M | 5 | 103 |
| A PHASE 3B, MULTI-CENTER, OPEN-LABEL TRIAL TO EVALUATE THE LONG TERM SAFETY OF TITRATED IMMEDIATE-RELEASE TOLVAPTAN OPC-41061, 30 MG TO 120 MGDAY, SPLIT DOSE IN SUBJECTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE | $6.4M | 3 | 153 |
| COMPARISON OF A LONG-ACTING INJECTABLE ANTIPSYCHOTIC VS CLINICIAN'S CHOICE EARLY IN TREATMENT TO BREAK THE CYCLE OF RELAPSE IN EARLY PHASE SCHIZOPHRENICS PRELAPSE | $5.4M | 0 | 3 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED, PARALLEL-GROUP TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CENTANAFADINE SUSTAINED-RELEASE TABLETS IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER TRIAL 405-201-00013 | $5.2M | 23 | 229 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF AVP-786 (DEUTERATED [D6]-DEXTROMETHORPHAN HYDROBROMIDE [D6-DM]/QUINIDINE SULFATE [Q]) FOR THE TREATMENT OF AGITATION IN PATIENTS WITH DEMENTIA OF THE ALZHEIMERS TYPE | $5.0M | 17 | 293 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED, PARALLEL-GROUP TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CENTANAFADINE SUSTAINED-RELEASE TABLETS IN ADULTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (TRIAL 405-201-00014) | $4.9M | 5 | 51 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED, PARALLEL-GROUP TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CENTANAFADINE SUSTAINED-RELEASE TABLETS IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER TRIAL 405-201-00014 | $4.8M | 0 | 46 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED, PARALLEL-GROUP TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CENTANAFADINE SUSTAINED-RELEASE TABLETS IN ADULTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (TRIAL 405-201-00013) | $4.1M | 4 | 49 |
| A Trial of Multiple-doses of Aripiprazole in Adults With Schizophrenia or Bipolar 1 Disorder | $4.1M | 0 | 16 |
| A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, ACTIVE- AND PLACEBO-CONTROLLED TRIAL OF THE SAFETY AND EFFICACY OF OPC-64005 IN THE TREATMENT OF ADULT ATTENTION-DEFICITHYPERACTIVITY DISORDER | $3.7M | 4 | 61 |
| AN OPEN-LABEL, 52-WEEK, MULTICENTER TRIAL EVALUATING THE LONG-TERM SAFETY AND TOLERABILITY OF CENTANAFADINE SUSTAINED-RELEASE TABLETS IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER | $3.6M | 2 | 99 |
| PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND ACTIVE-CONTROLLED TRIAL OF BREXPIPRAZOLE 1 - 3 MGDAY AS MONOTHERAPY OR AS COMBINATION THERAPY IN THE TREATMENT OF ADULTS WITH POST-TRAUMATIC STRESS DISORDER | $3.5M | 2 | 119 |
| AN OPEN-LABEL, SINGLE- AND MULTIPLE-DOSE, PHARMACOKINETIC, SAFETY, AND TOLERABILITY TRIAL OF ARIPIPRAZOLE LONG-ACTING INJECTABLE ADMINISTERED IN THE DELTOID OR GLUTEAL MUSCLE IN ADULT SUBJECTS WITH SCHIZOPHRENIA OR BIPOLAR I DISORDER | $3.1M | 0 | 6 |
| A PHASE IIIB MULTI-CENTER, OPEN-LABEL, MIRROR-IMAGE, STUDY IN ADULT SUBJECTS WITH SCHIZOPHRENIA TREATED PROSPECTIVELY FOR 6-MONTHS WITH ABILIFY MYCITE | $2.7M | 58 | 566 |
| A MULTICENTER, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY AND TOLERABILITY OF BREXPIPRAZOLE IN THE TREATMENT OF SUBJECTS WITH BIPOLAR I DISORDER | $2.6M | 2 | 94 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF AVP-786 (DEUDEXTROMETHORPHAN HYDROBROMIDE [D6 DM]/QUINIDINE SULFATE [Q]) FOR THE TREATMENT OF AGITATION IN PATIENTS WITH DEMENTIA OF THE ALZHEIMERS TYPE | $2.5M | 0 | 118 |
| BREXPIPRAZOLE AS COMBINATION THERAPY WITH SERTRALINE IN THE TREATMENT OF ADULTS WITH POST-TRAUMATIC STRESS DISORDER | $2.5M | 4 | 83 |
| BREXPIPRAZOLE AS COMBINATION THERAPY WITH SERTRALINE IN TREATMENT OF ADULTS WITH PTSD | $2.5M | 57 | 441 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF AVP-786 (DEUDEXTROMETHORPHAN HYDROBROMIDE [D6-DM]/QUINIDINE SULFATE [Q]) FOR THE TREATMENT OF AGITATION IN PATIENTS WITH DEMENTIA OF THE ALZHEIMERS TYPE | $2.5M | 0 | 126 |
| A Phase 2, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled Trial | $2.3M | 32 | 245 |
| A PHASE 3, 12-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 2-ARM, FIXED-DOSE TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF BREXPIPRAZOLE (OPC34712) IN THE TREATMENT OF SUBJECTS WITH AGITATION ASSOCIATED WITH DEMENTIA OF THE ALZHEIMERS TYPE | $2.2M | 5 | 53 |
Payments by Medical Specialty
Top Paid Doctors — Page 3
| Doctor | Specialty | Location | Total | 2022 |
|---|---|---|---|---|
| Dr. Jacqueline French, Md, MD | Neurology | New York, NY | $60,194 | $0 |
| Christoph Correll, Md, MD | Psychiatry | Glen Oaks, NY | $58,693 | $0 |
| Stuart Goldstein, Md, MD | Pediatric Nephrology | Cincinnati, OH | $57,512 | $0 |
| Dr. Daniel Karlin, M.d., M.a, M.D., M.A | Addiction Medicine | New York, NY | $57,346 | $0 |
| Augustus Rush, Md, MD | Psychiatry | Dallas, TX | $57,276 | $0 |
| J Easton, Md, MD | Neurology | Providence, RI | $56,059 | $0 |
| Lisa Guay-Woodford, Md, MD | Pediatric Nephrology | Washington, DC | $52,887 | $0 |
| Dana Rizk | Nephrology | Birmingham, AL | $50,341 | $0 |
| Dr. Charles Ellis, Md, MD | Dermatology | Ann Arbor, MI | $49,849 | $0 |
| Henry Nasrallah, Md, MD | Psychiatry | Cincinnati, OH | $49,077 | $0 |
| Boadie Dunlop, Md, MD | Psychiatry | Atlanta, GA | $48,951 | $0 |
| Dr. Elizabeth Lulaj, M.d, M.D | Student in an Organized Health Care Education/Training Program | Staten Island, NY | $47,200 | $0 |
| Dr. O'neill D'cruz, Md, MD | Neurology | Chapel Hill, NC | $46,410 | $0 |
| Dr. Mauricio Tohen, Md, Drph, Mba, MD, DRPH, MBA | Psychiatry | Albuquerque, NM | $45,061 | $0 |
| Biruh Workeneh, Md, MD | Internal Medicine | Houston, TX | $44,639 | $0 |
| Martha Sajatovic, Md, MD | Psychiatry | Cleveland, OH | $44,579 | $0 |
| Dr. Henrietta Ukwu, M.d, M.D | Research Study | Ambler, PA | $43,172 | $0 |
| Martin Farlow, Md, MD | Neurology | Indianapolis, IN | $43,113 | $0 |
| Neera Dahl, Md, MD | Nephrology | Rochester, MN | $41,979 | $0 |
| Dr. Rebecca Ahdoot, M.d, M.D | Nephrology | Orange, CA | $41,871 | $0 |
| Dr. Alfred Neugut, M.d., Ph.d, M.D., PH.D | Hematology & Oncology | New York, NY | $41,337 | $0 |
| Dr. Meyeon Park, Md, MD | Nephrology | San Francisco, CA | $40,427 | $0 |
| Jeffrey Newcorn, M.d, M.D | Child & Adolescent Psychiatry | New York, NY | $40,351 | $0 |
| Michal Mrug | Nephrology | Birmingham, AL | $38,924 | $0 |
| Lori Davis, Md, MD | Psychiatry | Tuscaloosa, AL | $38,886 | $0 |
Ad
Top Products
- REXULTI $116.1M
- TOLVAPTAN $16.5M
Associated Products (9)
- REXULTI $164.2M
- TOLVAPTAN $16.8M
- SAMSCA $7.0M
- BREXPIPRAZOLE $3.4M
- ABILIFY MYCITE $2.9M
- BREATHTEK $685,780
- ABILIFY $376,319
- REJOYN $194,004
- ABILIFY TABLET $16,152
Payment Categories
- Food & Beverage $694,916
- Consulting $20.0M
- Travel & Lodging $485,993
- Research $247.2M
- Royalties $198,678
About Otsuka Pharmaceutical Development & Commercialization, Inc.
Otsuka Pharmaceutical Development & Commercialization, Inc. has made $271.0M in payments to 9,266 healthcare providers, recorded across 27,284 transactions in the CMS Open Payments database. In 2024, the company paid $12.3M. The top product by payment volume is REXULTI ($116.1M).
Payments were distributed across 171 medical specialties. The top specialty by payment amount is Psychiatry ($8.7M to 2,168 doctors).
Payment categories include: Food & Beverage ($694,916), Consulting ($20.0M), Research ($247.2M), Travel & Lodging ($485,993), Royalties ($198,678).
Otsuka Pharmaceutical Development & Commercialization, Inc. is associated with 9 products in the CMS Open Payments database, including REXULTI, TOLVAPTAN, and SAMSCA.